Jamie Christensen - Jan 20, 2023 Form 4 Insider Report for Mirati Therapeutics, Inc. (MRTX)

Role: EVP, Chief Scientific Officer
Signature: /s/ Reena R. Desai, Attorney-in-Fact
Stock symbol: MRTX
Transactions as of: Jan 20, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/24/2023, 03:00 PM
Previous filing: Jan 19, 2023
Next filing: May 24, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRTX	Common Stock	Award	$0	+26.9K	+27.45%	$0.00	125K	Jan 20, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRTX	Employee Stock Option (Right to Buy)	Award	$0	+45.5K		$0.00	45.5K	Jan 20, 2023	Common Stock	45.5K	$45.66	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested.
F2	25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.